Published in Cancer Weekly, September 7th, 2004
Glivec, the only treatment currently available for the disease, is now fully approved by NICE for the first-line management of patients with GISTs and chronic myeloid leukemia in all stages of the disease and will be fully funded by the National Institutes of Health in accordance with all its licensed indications as recommended by NICE.
Professor Ian Judson, consultant medical oncologist, Royal Marsden...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.